| Nov 19, 2009 | 16:09 | XOMA Receives NASDAQ Determination Letter |
 | XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it received a letter from the staff of The NASDAQ Stock Market LLC on November 13, 2009 indicating that the NASDAQ staff has concluded that XOMA's previously-announced common share financing completed on September 30, 2009 did not comply with NASDAQ's Listing Rule 5635(d)(2). Listing Rule 5635(d)(2) requires that a company obtain shareholder approval for the issuance of common shares or securities exercisable for common shares equal to 20% or more of the common shares outstanding before the issuance for less than the greater of book or market value of the shares. Receipt of this letter has no effect on the current listing status of the common shares.
continued... |
|
| Nov 18, 2009 | 16:15 | Advocat Announces Details of First Annual Investor Day |
| Advocat Inc. (Nasdaq:AVCA) today announced the agenda for its first annual Investor Day to be held at company headquarters in Brentwood, Tennessee, on Monday, December 7th.
continued... |
|
| Nov 18, 2009 | 16:05 | Graymark Healthcare Reports Third Quarter 2009 Results |
| Graymark Healthcare Inc. (Nasdaq:GRMH) today announced results for the third quarter ended September 30, 2009.
continued... |
|
| Nov 18, 2009 | 09:46 | Nanosphere Announces FDA Submission of 510(k) Documentation for Its Verigene Cardiac Troponin I Assay |
 | Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it submitted a 510(k) application to the FDA for its cardiac troponin I test that the company believes will provide early and sensitive diagnosis of myocardial infarction and risk stratification for acute coronary syndromes.
continued... |
|
| Nov 18, 2009 | 02:05 | Evotec Wins German Government Research Grant |
| Evotec (Frankfurt:EVT) (TecDAX), a leading provider in the discovery and development of novel small molecule drugs, today announced that it has been granted up to EUR 2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection. Evotec will use its drug discovery platform and expertise in progressing this program towards the clinic, particularly making use of its high quality compound library and proprietary fragment-based drug discovery platform.
continued... |
|
| Nov 17, 2009 | 16:05 | Myriad Genetics to Present at the 21st Annual Piper Jaffray Health Care Conference |
 | Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at the 21st Annual Piper Jaffray Health Care Conference, at 9:30 a.m. Eastern on December 1, 2009, at the New York Palace Hotel in New York City.
continued... |
|
| Nov 17, 2009 | 15:47 | Capstone Therapeutics Announces Transfer to Nasdaq Capital Market |
 | Capstone Therapeutics (the "Company") (Nasdaq:CAPS) today announced that its application to transfer the listing of its common stock from The Nasdaq Global Market to The Nasdaq Capital Market has been approved by Nasdaq. This transfer will be effective at the opening of business on Friday, November 20, 2009, and the Company's common stock will continue to trade under the symbol "CAPS." The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Market. All companies listed on The Nasdaq Capital Market must meet certain financial requirements and comply with Nasdaq's corporate governance requirements.
continued... |
|
| Nov 17, 2009 | 12:30 | OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference |
 | OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim safety data from the FALCON (Fosbretabulin in Advanced Lung Oncology) study, a Phase 2, randomized, controlled study of ZYBRESTAT (fosbretabulin) in patients with advanced non-small cell lung cancer (NSCLC). The data from this planned interim safety analysis indicated that the combination of fosbretabulin with carboplatin and paclitaxel plus bevacizumab (Avastin(R)) appeared to be well-tolerated, and that there were no significant overlapping toxicities with bevacizumab. Notably, 5 of the 6 patient deaths during the evaluation period were due to disease progression and occurred in the control arm. The data were presented in a poster by Edward Garon, M.D., Assistant Professor of Medicine at the University of California, Los Angeles, principal investigator for the Phase 2 trial, at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. A further analysis of the efficacy and tolerability of this novel combination is expected to be presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO), scheduled for June 4-8, 2010 in Chicago, IL.
continued... |
|
| Nov 17, 2009 | 08:16 | Patient Portal Technologies Awarded a New Multi Year Contract With Taylor Hospital |
| Patient Portal Technologies, Inc. (OTCBB:PPRG) announced today that it has been awarded a five-year, million dollar plus contract from Crozer-Chester Medical Center, on behalf of its Taylor Hospital division, to provide a full range of its patient satisfaction services. Included in the service offering is management of the television and phone system, providing HealthCast, the bedside patient education platform and Instant Response, a patient response tool for non medical support.
continued... |
|
| Nov 17, 2009 | 08:00 | XOMA Appoints Jim Neal Vice President of Business Development |
| XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President, Business Development. Mr. Neal will oversee XOMA's business development strategy and lead the team to execute key licensing initiatives to build and support XOMA's proprietary therapeutic pipeline and biodefense programs, to market the company's antibody technologies and to assess commercial opportunities and develop product candidates commercially.
continued... |
|
| Nov 17, 2009 | 08:00 | Infinity's IPI-504 Named One of Windhover and Campbell Alliance's "Top 10 Projects to Watch" in Oncology |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey Tong, Ph.D., vice president, corporate and product development, will present an overview of IPI-504 (retaspimycin hydrochloride), the company's intravenous heat shock protein 90 (Hsp90) chaperone inhibitor, at the Therapeutic Area Partnerships event tomorrow, November 18, 2009 at 3:30 p.m. EST. The conference, being held November 17-19, in Boston, showcases Windhover and Campbell Alliance's 2009 "Top 10 Projects to Watch" and partnership opportunities in oncology.
continued... |
|
| Nov 17, 2009 | 07:00 | Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA |
 | Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that it has submitted to the U.S. Food and Drug Administration (FDA) its proposed protocol for a Surfaxin(R) (lucinactant) limited clinical trial. The protocol incorporates a clinical trial design that is primarily intended to assess a pharmacodynamic (PD) response following Surfaxin administration in preterm infants with Respiratory Distress Syndrome (RDS). Discovery Labs proposed this trial design in response to a comment by the FDA that a limited clinical trial could potentially resolve the key remaining issue for approval of Surfaxin for the prevention of RDS in premature infants.
continued... |
|
| Nov 16, 2009 | 09:33 | Millennium Biotechnologies Completes Recapitalization and Receives New Financing |
| Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTCBB:MBTG), a leader in the development, manufacturing and sales of targeted nutritional products in the Clinical and Sports Nutrition Markets, announced today that it has completed a recapitalization and elimination of over $14,000,000 of the current liabilities.
continued... |
|
| Nov 16, 2009 | 09:30 | Adelene Q. Perkins Named "Best Executive" at Annual Stevie(R) Awards Ceremony |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Adelene Q. Perkins, president and chief business officer, was named the 2009 "Best Executive: Non-Services Business" in the 6th Annual Stevie Awards for Women in Business, presented at the Annual Award Dinner and Ceremony held on November 13, 2009 in New York City.
continued... |
|
| Nov 16, 2009 | 09:00 | Elite Pharmaceuticals, Inc. to Host Quarterly Conference Call on Wednesday, November 18, 2009 |
| Elite Pharmaceuticals, Inc. (OTCBB:ELTP) today announced that it has scheduled a conference call for Wednesday, November 18, 2009 at 10:00 AM EST during which management will review quarterly earnings and provide a general corporate update. Company executives will also conduct a question and answer session following their remarks.
continued... |
|
| More >>
Total: 15 * all times are in the U.S. Eastern Time Zone
|
